IntestiCult™ Intestinal Organoid Growth Medium (Human)

IntestiCult™ Organoid Growth Medium (Human)

Cell culture medium for establishment and maintenance of human intestinal organoids

Skip to the beginning of the images gallery

Interested in trying ��ƽ��’s organoid products for your intestinal research? Fill out the form to request information about introductory offers.

IntestiCult™ Organoid Growth Medium (Human)

Cell culture medium for establishment and maintenance of human intestinal organoids

Size

1 Kit Request Pricing

Catalog #

(Select a product)

Cell culture medium for establishment and maintenance of human intestinal organoids

Request Pricing Request Pricing

Product Advantages

Convenient, in vitro system that recapitulates many key characteristics of the adult intestinal epithelium, including intra- and intercellular signaling, self-propagating stem cell niche, and functional transport into and out of the lumen

Complete medium formulation that delivers consistent results

Enables generation of intestinal organoids in one week

Easy-to-use format and optimized protocol

What's Included

IntestiCult™ OGM Human Basal Medium, 50 mL
Organoid Supplement, 50 mL

Request Pricing

Thank you for your interest in this product. Please provide us with your contact information and your local representative will contact you with a customized quote. Where appropriate, they can also assist you with a(n):

Estimated delivery time for your area

Product sample or exclusive offer

In-lab demonstration

By submitting this form, you are providing your consent to ��ƽ�� Technologies Canada Inc. and its subsidiaries and affiliates (“��ƽ��”) to collect and use your information, and send you newsletters and emails in accordance with our privacy policy. Please contact us with any questions that you may have. You can unsubscribe or change your email preferences at any time.

This site is protected by reCAPTCHA and the ��Ի��.

To see all required products for your protocol, please consult the Protocols and Documentation.

Gentle Cell Dissociation Reagent
cGMP, enzyme-free cell dissociation reagent
Organoid Culture Plates
Cell culture plates for easy and reproducible generation of organoids
DMEM/F-12 with 15 mM HEPES
Dulbecco's Modified Eagle's Medium/Nutrient Ham's Mixture F-12 (DMEM/F-12) with 15 mM HEPES buffer
Y-27632 (Dihydrochloride)
RHO/ROCK pathway inhibitor; Inhibits ROCK1 and ROCK2
Labeling Antibodies
Compatible antibodies for purity assessment of isolated cells

What Our Scientist Says

Organoids have truly expanded the limits of what's possible for in vitro studies of the intestinal epithelium. By providing optimized culture media and robust, approachable protocols, we are making these technologies more accessible to researchers.

Ryan ConderAssociate Director, Gastrointestinal Biology

Overview

Model key characteristics of the adult intestinal epithelium using intestinal organoids established and maintained with this complete medium formulation and optimized protocol. Using the easy-to-follow and robust protocol, you can derive organoids from human intestinal crypts in one week; organoid growth across donor samples, including those that are otherwise difficult to grow, is enabled by an enriched stem cell population.

Organoids grown in IntestiCult™ Organoid Growth Medium (Human) incorporate a functional lumen enclosed by a polarized intestinal epithelial cell layer and, for versatile modeling applications, can be further differentiated in 3D or in 2D as submerged monolayers or air-liquid interface (ALI) cultures using IntestiCult™ Organoid Differentiation Medium (Human; Catalog #100-0214).

Applications of intestinal organoid cultures include studying the development and function of intestinal epithelium, modeling intestinal diseases, and screening molecules for both efficacy and toxicity in an intestinal model. Intestinal organoid cultures can also be used for investigation of adult stem cell properties and for regenerative therapy approaches.

Learn how to culture human intestinal organoids in our On-Demand Intestinal Course or browse our Frequently Asked Questions (FAQs) about the organoid workflows using IntestiCult™. Additionally, download our detailed e-book Proven Protocols for Intestinal Organoid Culture: Getting Started with IntestiCult™ for a curated collection of intestinal organoid protocols.

Should you intend to use this product for commercial purposes, please contact HUB Organoids B.V. at for a commercial use license or for clarifications in relation to HUB Organoids B.V. licensing.

Specialized Media

Intestinal Cells

Human

Cell Culture, Differentiation, Expansion, Maintenance, Organoid Culture

IntestiCult

Disease Modeling, Epithelial Cell Biology, Stem Cell Biology

Data Figures

Figure 1. Primary Organoids Grown in IntestiCult™ Organoid Growth Medium (Human) are Fully Mature After 10-14 Days in Culture

Primary organoids were cultured from human colonic biopsy samples and grown in IntestiCult Organoid Growth Medium (Human). Organoids were imaged after (A) two days, (B) six days, (C) eight days and (D) ten days growth.

Figure 2. Organoids Grown in IntestiCult™ Organoid Growth Medium (Human) Display Markers of Human Intestinal Epithelial Cells

Immunofluorescence of organoids grown in IntestiCult™ Organoid Growth Medium (Human) showing colocalization of (A) DAPI, (B) EPCAM and (C) Ki67. (D) A merged image shows the position of actively proliferating (Ki67+) intestinal stem cells within the epithelial layer (EPCAM+).

Figure 3. Forskolin-Induced Swelling of Organoids Grown in IntestiCult™ Organoid Growth Medium (Human)

Organoids were treated with (A) 5 μM Forskolin or (B) DMSO and organoid area was measured at 0 minutes and 120 minutes. (C)Forskolin-treated organoids increased in size 33.5 ± 3.8% compared to 7.5 ± 0.8% for DMSO-treated organoids.

Figure 4. IntestiCult™ Organoid Growth Medium (Human) Supports the Growth of Organoids in Multiple Extracellular Matrices

Intestinal organoid cultures were prepared in IntestiCult™ Organoid Growth Medium (Human) and plated in (A) Matrigel® Growth Factor Reduced Basement Membrane Matrix (Corning® catalog # 356231), (B) Geltrex® LDEV-Free Reduced Growth Factor Basement Membrane Matrix (Gibco™ catalog # A1413202), (C) Cultrex® Reduced Growth Factor Basement Membrane Extract, Type 1 (R&D Systems™ catalog # 3433-005-R1), and (D) Cultrex® Reduced Growth Factor Basement Membrane Extract, Type 2 (R&D Systems™ catalog # 3533-005-02). Organoid cultures are imaged at the end of passage 4. All four extracellular matrices supported robust growth of human intestinal organoids. Scale bars = 250 μm.

Data and images of the MIMETAS OrganoReady Colon Organoid Plate

Figure 5. The MIMETAS OrganoReady® Colon Organoid Platform Uses IntestiCult™ to Create an Advanced Physiologically Relevant Model for Gastrointestinal Toxicity Testing and Barrier Integrity

(A) The OrganoReady® plate highlighting the microfluidic compartments.

(B) Schematic of the OrganoReady® microfluidic compartments where columns 1, 2, and 3 house the medium, a collagen-1 matrix, and the colon organoid tubule, respectively.

(C) Immunofluorescence staining of the colon organoid tubule confirms an adult tissue phenotype with the presence of goblet cells (Muc2), enterocytes (Occludin), and stem cells (Sox9). The 3D-lumenized structure provides apical (Ezrin) and basolateral (Integrin-β4) access to the polarized epithelium. Additionally, the organoid tubules show polarized and modulatable activity of expression of P-glycoprotein (Pgp).

(D) The OrganoReady® Colon Organoid platform supports toxicity testing, as demonstrated by dose-dependent measurements of TEER, LDH, and ATP following exposure to Afatinib (n = 4, N = 2). After 72 hrs of exposure, a dose dependent decrease in TEER, cytotoxicity, and cell viability was observed. For more information, please visit .

Protocols and Documentation

Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.

Document Type

Product Name

Catalog #

Lot #

Language

Document Type

Product Name

Catalog #

06010

Lot #

All

Language

English

Document Type

Product Name

Catalog #

06010

Lot #

All

Language

English

Document Type

Product Name

Catalog #

06010

Lot #

All

Language

English

Document Type

Product Name

Catalog #

06010

Lot #

All

Language

English

Document Type

Product Name

Catalog #

06010

Lot #

All

Language

English

Applications

This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.

Research Area

Workflow Stages

Workflow Stages for Intestinal Epithelial Cell Research

Tissue Dissociation

Cell Culture

Workflow Stages for Organoids

View All

Workflow Stages for Genome Editing

View All

Resources and Publications

An integrated patient-derived colon organoids platform as a functional model for nutraceutical and stress response. A. Costantino et al. iScience 2026 Jun

Abstract

Nutraceuticals are increasingly investigated for their capacity to modulate oxidative and inflammatory stress, yet preclinical testing still relies largely on immortalized cell lines or animal models that poorly recapitulate human epithelial complexity. To address this gap, we developed an integrated platform based on patient-derived colon organoids generated from non-tumoral mucosa and maintained under proliferative or differentiation conditions to model distinct epithelial states. The system combines millifluidic measurement of individual organoid mass, density, and diameter with bulk RNA sequencing and digital PCR profiling to enable multiparametric characterization. Transcriptional analysis revealed state-specific gene programs and shifts in epithelial and immune-related pathways, while biophysical measurements captured structural remodeling. In this pilot validation, a defined oxidative insult followed by nutraceutical treatment elicited coordinated transcriptional and phenotypic responses. This integrated approach provides a scalable and physiologically relevant framework for functional nutraceutical profiling and mechanistic studies of epithelial stress responses.

Inducing Targeted, Caspase-Independent Apoptosis with New Chimeric Proteins for Treatment of Solid Cancers. O. Melloul et al. Cancers 2025 Mar

Abstract

Background: Most newly developed anticancer treatments trigger tumor cell death through apoptosis, for which involvement of caspases activity is essential. However, numerous mutations in apoptotic pathways that lead to cancer and favor resistance to apoptosis are known; most are related to caspase-dependent apoptosis pathways and thus have low efficacy. To overcome these limitations, we constructed a novel chimeric protein, GnRH-AIF, using a gonadotropin-releasing hormone (GnRH) analog as a targeting moiety and the apoptosis-inducing factor (AIF) in its cleaved form as a killing moiety, fused at the cDNA level. AIF has a crucial role in the caspase-independent apoptotic pathway. A wide variety of solid tumors overexpress GnRH-receptors (GnRH-R) that are targeted by the new GnRH-AIF chimeric protein. Methods and Results: In this study, we constructed, expressed, and highly purified GnRH-AIF chimeric proteins. We demonstrated the ability of the chimera to enter and specifically and very efficiently kill solid cancer cell lines overexpressing GnRH-R. Most importantly, upon its entry, GnRH-AIFs translocate to the nucleus where it causes DNA fragmentation leading to a direct caspase-independent apoptotic death. As AIFs lack nuclease activity, our findings also emphasize that cell death induced by GnRH-AIF is dependent on the presence of the ENDOG and PPIA proteins, known to participate in the formation of a DNA-degradosome complex. Finally, we demonstrated the high anti-tumor efficacy of the GnRH-AIF ex vivo, in a human, colon cancer organoid model. Conclusions: Our study shows the potential of using a GnRH-AIF chimeric protein as a novel approach to treat solid cancers that overexpress GnRH-R, via a caspase-independent apoptotic pathway.

Lack of biochemical signalling in GelMA leads to polarity reversion in intestinal organoids independent from mechanoreciprocity. L. Vanhove et al. Journal of tissue engineering 2025 Jun

Abstract

Xenogeneic tumour origin and batch-to-batch variability of Engelbreth-Holm-Swarm sarcoma tumour cell-derived hydrogels (Matrigel, Cultrex) limit the biomedical application of organoids in tissue engineering. The gelatin-methacryloyl (GelMA) hydrogels represent a defined, tunable, and GMP-friendly alternative, but they are rarely studied as alternative to Matrigel. Here, we studied effects of mechanical properties of GelMA and addition of laminin-111 on encapsulation and growth of small intestinal organoids. GelMA-embedded organoids displayed polarity reversion, resulting in apical-out and apical-basal phenotypes, independent from the matrix stiffness. Addition of laminin-111 softened hydrogels and also resulted in a partial restoration of the basal-out phenotype. Interestingly, despite the incomplete polarity restoration, GelMA-organoids still showed minor growth. GelMA stiffness and concentration influenced the transition from 3D to 2D organoid cultures. Collectively, our study confirms that tuning of GelMA mechanical properties alone cannot recapitulate the basal membrane matrix. However, controlled polarity reversion offers a tool for engineering organoids and enabling apical membrane access.

View All Publications

Related Products

Interested in trying ��ƽ��’s organoid products for your intestinal research? Fill out the form to request information about introductory offers.

Legal Statement:

This product was developed under a license to intellectual property owned by Hubrecht Organoid Technology (HUB). This product is sold for research use only. Purchase of this product does not include the right to use it for drug screening aiming for commercial gain, equipment validation, biobanking, or for other commercial purposes. Purchasers wishing to use the product for purposes other than basic research use should contact HUB at www.huborganoids.nl to obtain a further license. Purchasers may apply for a License from HUB, which will not be unreasonably withheld by HUB.

Quality Statement:

PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT ��ƽ��, REFER TO WWW.��ƽ��.COM/COMPLIANCE.

Safety Statement:

CA WARNING: This product can expose you to Progesterone which is known to the State of California to cause cancer. For more information go to

�����ƽ��

IntestiCult™ Organoid Growth Medium (Human)

Cell culture medium for establishment and maintenance of human intestinal organoids

IntestiCult™ Organoid Growth Medium (Human)

Cell culture medium for establishment and maintenance of human intestinal organoids

Product Advantages

What's Included

Request Pricing

What Our Scientist Says

Overview

Data Figures

Protocols and Documentation

Applications

Resources and Publications

Educational Materials (62)

Publications (47)

Abstract

Abstract

Abstract

Related Products

Item added to your cart

��ƽ��